drug maker Pliva, the largest East European pharmaceutical
firm by sales, has opened a research facility at Corlim
in Goa. The Centre for Bioequivalency Studies, inaugurated
by Goa governor S C Jami on Wednesday, will further boost
its generics business, Pliva said in a statement.
is Pliva's first greenfield investment in India and our
fourth research centre. We are pleased that this centre
will help Pliva boost its capacity for developing generic
drugs," CEO Zeljko Covic said in the statement.
state-of-art Rs20-crore research and development facility
of Pliva Research (India) Pvt Ltd, a subsidiary of Pliva,
is the fourth R&D centre within the group. The new
facility, covering an area of over 4,000-square metres,
is expected to provide direct employment to 55 people.
Pilva has expansion plans and expects employee strength
to double by the year 2008.
chief minister Pratapsing Rane, Croatian ambassador to
India Dino Debeljuh and Pliva's executive director for
generic research and development Zdravka Knezevic were
present at the occasion.
a press conference ahead of the inauguration of the facility,
Mohammad Zahirul Islam Khan, chairman, Pliva India said
the centre will focus on conducting bio-equivalence, bio-availability
and pharmacokinetic studies for the company's generic
products pipeline. The Goa unit will complement Pliva's
existing R&D capabilities established in the areas
of chemistry, bio-technology and formulation development,
already operating in Croatia, Poland and the Czech Republic,
Dr Khan added.
Goa facility, he said, is a 100 per cent export-oriented
unit and meets the highest standards for domestic and
has tie-ups with a number of Indian companies in both
R&D and business development, including Dr Reddy's
Laboratories, in the area of oncology and Unichem, in
the areas of development and
operates in more than 30 countries and sees the generic
business, including biotechnology, as its driving force.